Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.
- DOI
- 10.1016/j.ctarc.2025.100979
- Published
- 2025
- Container
- Cancer treatment and research communications
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctarc.2025.100979,
title = {Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.},
author = {Soeroso NN and Syahruddin E and Soliha C and Wulandari L and Setijadi AR and Ermayanti S and Pratiwi SD and Infianto A and Andayani N and Munir SM and Pratama AD and Kusumawardani IAJD and Haryati H and Duyan N and Hanif MA and Lim DW},
year = {2025},
journal = {Cancer treatment and research communications},
doi = {10.1016/j.ctarc.2025.100979},
url = {https://doi.org/10.1016/j.ctarc.2025.100979}
}RIS
TY - JOUR TI - Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia. AU - Soeroso NN AU - Syahruddin E AU - Soliha C AU - Wulandari L AU - Setijadi AR AU - Ermayanti S AU - Pratiwi SD AU - Infianto A AU - Andayani N AU - Munir SM AU - Pratama AD AU - Kusumawardani IAJD AU - Haryati H AU - Duyan N AU - Hanif MA AU - Lim DW PY - 2025 JO - Cancer treatment and research communications DO - 10.1016/j.ctarc.2025.100979 UR - https://doi.org/10.1016/j.ctarc.2025.100979 ER -
APA
NN, S., E, S., C, S., L, W., AR, S., S, E., SD, P., A, I., N, A., SM, M., AD, P., IAJD, K., H, H., N, D., MA, H., & DW, L. (2025). Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia.. Cancer treatment and research communications. https://doi.org/10.1016/j.ctarc.2025.100979
Source records
- pubmed · retrieved 2026-09-26T19:38:42.801Z